Liver illustration: Shutterstock

Is there room for MASH drugs in a GLP-1 world?

For years, drug de­vel­op­ers work­ing to treat an ad­vanced form of fat­ty liv­er dis­ease known as MASH were chas­ing wide-open ter­rain. There were no prod­ucts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.